Mounjaro and Ozempic warning for holiday travel insurance

Travel insurance providers are warning that the growing number of Brits turning to these breakthrough drugs for weight management could lose their cover and face huge medical bills abroad if they don't declare their usage when arranging travel insurance.
Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: https://t.co/03msJjjTU9 pic.twitter.com/tHs6lyJHc4 — We are Primary Care (@PrimaryCareNHS) June 12, 2025
Many don't want to admit they are taking the weight-loss drugs, or think that if they buy it privately online, it doesn't need to be declared.
Niraj Mamtora, director at Forum Insurance, says: 'Weight-loss medications like Ozempic are transforming lives across the UK, but too many travellers don't realise the insurance implications. If you're using these drugs, you must declare both the medication and the condition it's prescribed for.
'Failure to do so is not a minor oversight - it's a serious breach of your travel insurance contract. If you need medical help overseas and haven't declared your medication, your claim can be refused and your policy cancelled. The financial consequences can be severe.'
What happens if you don't disclose weight-loss jabs on your travel insurance?
'Non-disclosure is a gamble that's simply not worth taking," says Niraj.
"If you don't declare your medication or the underlying condition, your insurer is within their rights to refuse any claim, even if it seems unrelated.
'Many travellers only discover too late that their travel insurance claims are rejected, leaving them without support and facing potentially huge bills.
Do I Need Travel Insurance?
"With the average medical claim abroad now exceeding £1,700, and costs rising significantly with age, being properly covered is more important than ever.'
'Skinny Jab' weight loss medication is surging
According to The Pharmacist website 1.5 million UK citizens used weight-loss jabs in March 2025, and the number is believed to be growing each month.
'Recent NHS data shows that between March 2024 and February 2025, more than 83,000 unique patients in England were dispensed Ozempic, while over 344,000 people received a prescription for weight-loss medications overall in the past year," says Niraj.
'With new drugs entering the market and millions more eligible for these treatments, the number of Brits travelling with prescription weight-loss medication is set to rise further.'
Recommended reading:
What to do if you are travelling abroad while taking weight-loss medication
Declare all pre-existing medical conditions and any medications, including Ozempic, Wegovy, and Mounjaro, when purchasing travel insurance. If you are taking medication without a prescription or for off-label use, you must disclose this, as it can affect your travel cover. Carry a copy of your prescription or a doctor's letter when travelling with medication, and check the rules of your destination country regarding bringing in prescription drugs.
Remember that insurance claims related to undeclared conditions or medications can be refused, even if the issue seems unrelated.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Daily Mirror

3 hours ago

• Daily Mirror

'We made a change after Covid that's let us quit our jobs to travel the world'

Ryan Losasso and Jade Beaty, 30, are now known as Live The Dash and travel across the world filming their exploits for their TikTok account, which is followed by 505,000 people A couple quit their desk jobs and now travel the world full-time after discovering what they had captured on holiday. Ryan Losasso and Jade Beaty, 30, are now known as Live The Dash, one of the biggest UK travel creators with 505,000 followers on TikTok. They live a life many dream of, getting paid to whizz around the world to intriguing destinations. ‌ The advertising workers had not planned to become full-time TikTok content creators. In fact, it wasn't until they returned from a big six-month trip at the turn of the Covid lockdowns that they realised what they were sitting on. ‌ "We had all this video content when the world shut down, and we had a lot of time on our hands. So we turned to this huge stock of footage," Ryan told the Mirror. "We set ourselves a challenge of posting a video every day for 30 days. Then when some of that did really well, it spurred us on. We continued to post every day for six months." Do you have a travel story to share? Email webtravel@ READ MORE: Tourist warning to 10 million as Europe's hottest capital on alert Jade added: "It was surprising how quickly we got through that content. On a walk in Spain, the videos were doing quite well, and we realised we were going to run out of content soon. We started joking that we'd start going on trips." At first, the couple juggled their desk jobs with travel, booking themselves onto the cheapest flight out after they clocked off on a Friday and returning on Sunday. Two years ago, they decided to go full time. The risk has clearly paid off, as Jade and Ryan are among the most watched travel TikTok channels and won the platform's Travel Award for 2024. Part of the secret to their success is putting in the research hours before they go on a trip and then only travelling when they've landed on a great idea. That might be heading to New York to see if the hallowed 'dollar slice' of pizza can still be purchased, or around the UK in search for a genuine 99p 99 whippy. ‌ They've also spent the night on the fastest sleeper train in the world, which rushes snoozing passengers from Hong Kong to Shanghai. "Was it amazing? The tech is amazing, but you're sharing with three other strangers. It reaches 270 mph, but it's super smooth," Ryan explained. "For TikTok specifically, we have our hooks before we go. We film all we can, we film the journey, we film two intros, two hooks. We bet on all the horses." The search for something new that will engage their audiences takes the pair to places they might otherwise not have visited, which often turn out to be the most enjoyable. READ MORE: Brits warned of travel chaos as European airport hit by 10th walkout in 45 days "Somewhere I wasn't expecting much from was Weston-super-mare. It had a lot of cheap whippies. It is obviously a faded Victorian seaside town, but the beach is gorgeous," Ryan said. ‌ Jade added: "We also like to hunt out weird hotels. We stayed in a cow cabin with unlimited free milk, near Ed Sheeran's hometown, called Easton Farm Park. We also stayed in these huge tree houses in Derby." The old adage of 'if you do what you love, you'll never work a day in your life' seems true in the couple's case. They still have the travel bug and are hugely excited by their trips. Part of that means pushing themselves to engage with people they meet along the way. "We have this rule that whenever we're on the plane, we have to speak to the person next to us. One guy told us 'do what excites you'. Six years later, we still tell ourselves that. We call it Conrad's message." ‌ The couple also recommends running every day and practicing good communication for travelling couples who want to avoid arguments while on the road. In terms of finding inspiration, they recommend using the adjustable 'For You' feed on TikTok. It is now possible to customise content preferences so you can see more or less of certain content in topics from over 10 categories – including travel, sports, nature, and food and drink An AI-powered 'smart keyword filter" that allows users to limit content they don't want to see'. "The For You feed is the heart of TikTok, a way for us to discover new content. We use the new features, manage topics, and think it's really cool that you can filter which topics you want to see more or less of."

South Wales Guardian

3 hours ago

• South Wales Guardian

Weight loss pill shows promise in new trial

An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

Leader Live

3 hours ago

• Leader Live

Weight loss pill shows promise in new trial

An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.